Mumbai, March 4 -- The product is the generic equivalent of Pomalyst Capsules of BMS Pharmaceuticals Corp. Eugia Pharma Specialities was among the First-to-File (FTF) ANDA applicants. Manufacturing will take place at Eugia Unit-I.

Pomalidomide, a third-generation immunomodulatory drug (IMiD), is used in combination with dexamethasone, and sometimes bortezomib, for relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals,...